Clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation pyrrolobenzodiazepine (“PBD”) technology to which we have proprietary rights for our targets. We are leveraging our R&D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, ADCT-402, ADCT-301 and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-301 and ADCT-601, and two preclinical product candidates, ADCT-701 and ADCT-901. We retain worldwide development and commercialization rights to all of our product candidates, other than ADCT-301 for which we have a collaboration and license agreement with Genmab A/S (“Genmab”).

Two lead product candidates, ADCT-402 and ADCT-301, have demonstrated significant clinical activity in heavily pre-treated patients, while maintaining manageable tolerability profiles. We are evaluating ADCT-402 in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”). 

ADC Therapeutics SA

Clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation pyrrolobenzodiazepine (“PBD”) technology to which we have proprietary rights for our targets. We are leveraging our R&D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, ADCT-402, ADCT-301 and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-301 and ADCT-601, and two preclinical product candidates, ADCT-701 and ADCT-901. We retain worldwide development and commercialization rights to all of our product candidates, other than ADCT-301 for which we have a collaboration and license agreement with Genmab A/S (“Genmab”).

Should you buy, sell, or hold ADC Therapeutics SA (ADCT) ?

ADC Therapeutics SA (ADCT) : Buy or Sell